Detalles de la búsqueda
1.
Proteogenomic Data Integration Reveals CXCL10 as a Potentially Downstream Causal Mediator for IL-6 Signaling on Atherosclerosis.
Circulation
; 149(9): 669-683, 2024 02 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38152968
2.
Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial.
Eur Heart J
; 37(30): 2406-13, 2016 Aug 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27161611
3.
Proteogenomic integration reveals CXCL10 as a potentially downstream causal mediator for IL-6 signaling on atherosclerosis.
medRxiv
; 2023 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37034659
4.
Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab.
Open Heart
; 10(2)2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37591633
5.
Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trial.
EBioMedicine
; 80: 104013, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35504178
6.
Tocilizumab increases citrullinated histone 3 in non-ST segment elevation myocardial infarction.
Open Heart
; 8(1)2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33972404
7.
Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction.
J Am Coll Cardiol
; 77(15): 1845-1855, 2021 04 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33858620
8.
Novel Insights Into the Effects of Interleukin 6 Antagonism in Non-ST-Segment-Elevation Myocardial Infarction Employing the SOMAscan Proteomics Platform.
J Am Heart Assoc
; 9(12): e015628, 2020 06 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-32515246
9.
Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction.
Int J Cardiol
; 274: 348-350, 2019 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29961573
10.
Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI).
Open Heart
; 6(2): e001108, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31673391
11.
Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction.
Open Heart
; 5(2): e000765, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30258647
12.
Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1ß in non-ST-elevation myocardial infarction.
Int J Cardiol
; 271: 1-7, 2018 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29961572
13.
IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction.
Front Immunol
; 9: 2035, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30258440
14.
Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction.
Heart
; 103(19): 1521-1527, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28432157
15.
Targeting IL-6 Trans-Signaling: Amplifying the Benefits of IL-6 Inhibition in Myocardial Infarction.
JACC Basic Transl Sci
; 6(5): 444-446, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-34102669
Resultados
1 -
15
de 15
1
Próxima >
>>